PubMed چکیده/رکورد

Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: Urine cytology is recommended for noninvasive detection of urothelial carcinoma (UC) but shows limited sensitivity, particularly in low-grade disease. Keratin 17 (K17) has emerged as a promising immunocytochemical marker. This study evaluated the diagnostic performance and interobserver agreement of K17 in a routine setting. METHODS: This prospective cross-sectional study included 184 urine samples from patients undergoing diagnostic evaluation for suspected UC. K17 immunocytochemistry was performed with a fully automated platform and independently evaluated by two blinded raters. Cytology was classified according to The Paris System for Reporting Urinary Cytology. UC status was determined by histology when available or by follow-up and multidisciplinary assessment. Diagnostic accuracy was assessed by receiver operating characteristic (ROC) analysis; interobserver reliability was assessed with the Cohen κ and intraclass correlation coefficient (ICC). Multivariable logistic regression evaluated combined diagnostic approaches. RESULTS: K17 expression was significantly higher in UC than in non-UC samples (p < .001). Across raters, area under the ROC curve (AUC) values ranged from 0.68 to 0.71. Sensitivity was 52.9%-65.9%, with a specificity of 73.7%-82.8%. Sensitivity ranged from 45.5% to 54.5% for low-grade tumors and from 57.7% to 73.1% for high-grade tumors. In stage-based analyses, sensitivity was 49.2%-61.5% for non-muscle-invasive UC and 65%-80% for muscle-invasive UC. Combining K17 with cytology numerically improved diagnostic discrimination (AUC value, 0.76; 95% CI, 0.69-0.83). Interobserver agreement was moderate to substantial (κ = 0.684; ICC, 0.653). Limitations included single-center design, partial histological verification (81%), and post hoc optimized cutoffs. CONCLUSIONS: K17 immunocytochemistry is a reproducible adjunct to urine cytology, with moderate diagnostic performance. It may warrant further evaluation as an adjunctive marker, particularly in low-grade and cytologically equivocal cases.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

AB_563797biomarkerscarcinomacytodiagnosisimmunocytochemistrykeratin 17tumorsurinary bladder neoplasms
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

A case report of primary prostate intravascular large B-cell lymphoma.

RATIONALE: Primary intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive extranodal lymphoma that rarely affects the prostate. Its nonspecific clinical and laboratory features often lead to misdiagnosis as benign prostatic hyperplasia (BPH) or prostatitis, delaying appropriate treatment. We report a case of primary prostatic IVLBCL initially misdiagnosed as BPH, highlighting the diagnostic challenges and the importance …

PubMed2026

An immunohistochemical based assessment of murine double minute 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) in jaw osteosarcoma and benign osseous lesions.

UNLABELLED: The diagnosis of primary bone tumours of the jaw often presents as a diagnostic dilemma. Overlap in clinical, radiological, and histological features between benign lesions like juvenile trabecular ossifying fibroma (JTOF); osteoblastoma (OB) and malignant tumours like low-grade osteosarcoma (LGOS) makes the diagnosis challenging. While osteosarcoma is a malignant tumour with poor prognosis requiring aggressive treatment, b…

PubMed2026

The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer.

PURPOSE: The antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and datopotamab deruxtecan target trophoblast cell surface antigen 2 (TROP-2) and have shown significant efficacy in HER2-negative metastatic breast cancer (mBC). As TROP-2 may serve as a target across multiple treatment lines, detailed information on TROP-2 expression over time is of great interest. METHODS: TROP-2 expression was analyzed in breast cancer (BC) sam…

PubMed2026

Mucin expression in pancreatic ductal adenocarcinoma cell lines in 2D and 3D cultures: A proteomic and immunocytochemical analysis.

Pancreatic ductal adenocarcinoma (PDAC) exhibits diverse phenotypes, including epithelial and mesenchymal characteristics, yet these features have not been effectively translated into clinical applications. Mucins are implicated in tumor progression and therapeutic resistance and are considered potential diagnostic and therapeutic targets. In this study, five epithelial and three mesenchymal PDAC cell lines were cultured under two-dime…